EMERYVILLE, Calif., July 26, 2022 /PRNewswire/ Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced Otsuka Pharmaceuticals, a leading pharmaceutical company, has implemented the use of the Berkeley Lights Beacon system for antibody discovery,as well as cell and gene therapy and cell line development research. Since acquiring the Beacon Platform in October 2021, Otsuka Pharmaceutical scientists have been developing significant expertise in using the Berkeley Lights technology and workflows. Specifically, the Beacon Platform has enabled them to expand their antibody discovery capacity beyond traditional hybridoma techniques. On top of the antibody discovery expertise, Otsuka will be leveraging the Beacon technology and workflows for use in the challenging field of cell and gene therapy. With the use of the Beacon system for research in cell and gene therapy, they can work rapidly and efficiently towards new discoveries. Yue Geng, Ph.D, general manager
DUBLIN (BUSINESS WIRE) The "U.S. Digital Therapeutics Market - Industry Outlook and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.Digital therapeutics plays a significant role in the treatment and disease management of various chronic and mental health conditions. It presents poten.
29.06.2022 - Leverages Mindset’s Platform Technology for Efficient Delivery of CNS TherapeuticsTORONTO, June 29, 2022 (GLOBE NEWSWIRE) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development .